8月20日周三盘中，歌礼制药-B（01672.HK）股价大跌5.03%，引起市场关注。此次下跌主要受到公司近期配股行为及高沽空比率的双重影响。
据悉，歌礼制药以先旧后新方式进行配股，配股价为每股16.45港元，共筹集资金总额4.74亿港元，净额约4.68亿港元。公司表示，约90%的募集资金将用于其皮下注射多肽及口服多肽候选药物有关的肥胖症临床试验研发，剩余10%将用作营运资金及其他一般公司用途。这一举措虽然有利于公司的长期发展，但短期内可能对股价造成压力。
此外，数据显示，歌礼制药在前一交易日的沽空比率高达29.51%，较过去两个月日均沽空水平高出3.54倍，反映出市场对该股票的看空情绪较重。高沽空比率可能进一步加剧了股价的下跌趋势。投资者应密切关注公司后续发展及市场情绪变化，谨慎评估投资风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.